ATP5ME

Across TCGA pan-cancer cohorts, ATP5ME mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP5ME data layer compared with 26 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATP5ME mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5ME expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where ATP5ME mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.444	0.788	.001	38	view →
HNSC	DFS	Median	IV	0.811	0.556	.019	15	view →
CCRCC	DFS	Median	All	0.915	0.537	.003	12	view →
OV	DFS	Tertile	All	0.922	0.484	.048	8	view →
LSCC	OS	Tertile	All	1.000	0.922	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP5ME–LUAD (DFS)

Open the LUAD breakdown →